This article introduces FRα targets and FRα ADCs in clinical trials. There is only one FRα targeting ADC for ovarian cancer - mirvetuximab soravtansine-gynx (Elahere) and a few in clinical trials.
Like this book? You can publish your book online for free in a few
minutes!